Liver cancer treatment depends on the size and number of tumors, how well your liver is functioning, and whether the cancer has spread beyond the liver. Options range from surgery that can potentially cure the disease to drug therapies that extend life when the cancer is more advanced. The five-year survival rate for liver cancer caught while it’s still confined to the liver is 37.4%, dropping to 13.4% when it has spread to nearby lymph nodes and 3.6% when it has reached distant organs. Getting the right treatment matched to your specific situation is what makes the biggest difference.
Why Liver Function Shapes Your Options
Your liver’s overall health matters as much as the tumor itself. Doctors assess liver function using a scoring system called Child-Pugh, which grades the liver from A (healthy) to C (severely impaired) based on factors like protein levels, bilirubin, fluid buildup, and mental clarity. Most aggressive treatments, including immunotherapy and surgery, are safest and most effective when liver function is well preserved (Class A). Patients with a Class A score who receive immunotherapy have a median overall survival of 22.5 months, while those with moderately impaired function (Class B) see that drop to roughly 5.7 months.
This doesn’t mean people with some liver impairment are automatically excluded. Recent real-world data show that a select group of patients with mildly impaired function, specifically those without significant fluid buildup or confusion from liver disease, can still benefit from combination immunotherapy with outcomes comparable to some Class A patients. But the core principle holds: the healthier the surrounding liver tissue, the more treatment doors are open to you.
Surgery: Resection and Transplant
When the cancer is caught early and the liver is functioning well, surgical removal of the tumor (partial hepatectomy) offers the best chance of a cure. Surgeons remove the portion of the liver containing the cancer, and the remaining liver regenerates over time. After open surgery, expect a hospital stay of up to a week, followed by four to eight weeks of recovery at home. Full return to normal activities typically takes about 12 weeks. If the surgery is done with a minimally invasive approach (laparoscopic or robotic), home recovery shortens to two to four weeks, with a return to normal life in six to eight weeks.
Liver transplant replaces the entire diseased liver, treating both the cancer and the underlying liver disease at once. Eligibility follows strict size limits known as the Milan criteria: either a single tumor 5 cm or smaller, or two to three tumors each 3 cm or smaller. Some centers use slightly expanded criteria, allowing a single tumor up to 6.5 cm or two to three tumors each up to 4.5 cm as long as the total tumor diameter stays under 8 cm. For tumors that are too large to qualify immediately, doctors may use other treatments to shrink them first, a process called downstaging, with the goal of bringing the cancer within transplant-eligible limits.
Ablation for Smaller Tumors
When surgery isn’t an option, whether because of tumor location, overall health, or limited liver function, ablation destroys tumors in place without removing them. The two most common methods use heat: radiofrequency ablation (RFA) sends electrical currents through a needle-thin probe inserted into the tumor, while microwave ablation (MWA) uses electromagnetic energy to generate higher temperatures.
Both techniques work best on tumors under 5 cm, with RFA considered especially effective for tumors smaller than 3 cm. A meta-analysis comparing the two approaches across hundreds of patients found no significant difference in incomplete treatment rates, complications, recurrence, or long-term cancer outcomes for tumors under 5 cm. In practice, the choice between them often comes down to tumor location and the treating physician’s experience. Ablation is sometimes used alongside other treatments or as a bridge therapy to keep cancer in check while a patient awaits a liver transplant.
Embolization and Internal Radiation
For tumors that are too large for ablation but haven’t spread outside the liver, embolization-based treatments target the tumor’s blood supply. The liver is unique in that it receives blood from two sources: the hepatic artery and the portal vein. Tumors feed primarily from the hepatic artery, so blocking that supply starves the cancer while the rest of the liver continues to function through the portal vein.
One increasingly used approach is radioembolization, which delivers tiny radioactive beads (Yttrium-90) directly into the arteries feeding the tumor. The beads lodge in the tumor’s blood vessels, delivering concentrated radiation from the inside while largely sparing healthy tissue. Clinical data from a five-year institutional study showed an objective response rate of 83.3% on six-month imaging, meaning the majority of treated tumors shrank significantly. This technique also serves as a bridge or downstaging tool before transplant.
Targeted Radiation Therapy
Stereotactic body radiation therapy (SBRT) delivers highly focused, high-dose radiation beams to the tumor over three to five treatment sessions. It achieves local control rates between 75% and 95% for tumors that can’t be surgically removed. SBRT is particularly useful for patients who aren’t candidates for ablation or embolization, or as a bridging strategy before liver transplant. In one study, patients both within and outside transplant eligibility criteria received SBRT, either to hold the cancer in place while awaiting transplant or to shrink tumors enough to qualify.
Advanced imaging techniques now allow radiation oncologists to map which parts of the liver are still functioning well and steer radiation away from those areas. This is especially valuable for patients with cirrhosis, where preserving every bit of working liver tissue matters.
Immunotherapy and Drug Treatments
When liver cancer can’t be treated with surgery or local therapies, systemic drug treatment becomes the primary approach. The treatment landscape has shifted dramatically toward immunotherapy-based combinations as the preferred first option.
The combination of an immune checkpoint inhibitor with an anti-angiogenic drug (which cuts off the tumor’s blood vessel growth) has become a standard first-line approach. Real-world data show this combination achieves a median overall survival of roughly 19.7 months, compared to 14.4 months for an older targeted therapy alone. Newer combinations are pushing those numbers further: one phase III trial reported a median overall survival of 23.8 months, and another showed 22.1 months, both significantly outperforming older single-drug options.
A dual immunotherapy approach, combining two different types of immune checkpoint drugs, has also shown strong results with durable responses, positioning it as another potential first-line choice for people with unresectable liver cancer. The choice between these regimens depends on your liver function, overall health, and whether you have conditions like autoimmune disease or a history of organ transplant that might make certain immune-based treatments riskier.
For patients whose cancer progresses on first-line therapy, several targeted drugs that block tumor growth signals remain available as later-line options. Lenvatinib, for example, provides a median progression-free survival of about 5.2 months compared to 3.3 months for sorafenib, one of the original targeted drugs approved for liver cancer.
Managing Symptoms in Advanced Disease
When liver cancer is advanced, symptom management becomes a central part of care. The most common complications stem from the cancer’s effect on liver function itself. Fluid accumulation in the abdomen (ascites) is managed with dietary sodium restriction, medications that help the body shed excess fluid, and in some cases a procedure to drain the fluid directly. Confusion or mental fogginess caused by toxin buildup (hepatic encephalopathy) is treated with medications that help clear those toxins through the gut.
Palliative care in liver cancer isn’t limited to end-of-life situations. It can run alongside active cancer treatment at any stage, focusing on pain control, nutrition, energy levels, and emotional well-being. Hepatologists often manage these liver-specific symptoms directly, coordinating with palliative care specialists when needed to address the full range of physical and psychological effects the disease can bring.
How Treatment Decisions Come Together
Liver cancer treatment is rarely a single intervention. Many patients move through a sequence: ablation or embolization to control the tumor, followed by transplant evaluation, or immunotherapy to shrink a tumor enough to reconsider surgery. The treatment plan is built around three intersecting factors: the number and size of tumors, the degree of liver damage from underlying disease like cirrhosis or hepatitis, and your overall physical condition.
A multidisciplinary tumor board, typically including a hepatologist, surgeon, oncologist, transplant specialist, and interventional radiologist, reviews these factors together. If you’ve been diagnosed with liver cancer, this team-based approach gives you the best chance of landing on a treatment strategy that fits both the cancer and your body’s ability to tolerate treatment.